eli-lilly
2 stories tagged "eli-lilly"
Metabolic & Weight
Retatrutide's Triple-Receptor Triumph Came With a One-in-Five Skin-Sensation Signal Nobody Wanted to Linger On
Eli Lilly's investigational retatrutide hit bariatric-surgery-level weight loss at ADA 2026. The highest-dose arm of TRIUMPH-4 also saw 20.9% of patients report abnormal skin sensations, and a small cardiac imbalance turned up in the type-2 trial. Both got far less stage time than the headline numbe
Metabolic & WeightLilly's triple agonist hit 30% weight loss. The glucagon bet is why.
Lilly's triple agonist hit nearly 30% weight loss at 104 weeks at ADA 2026. The glucagon bet is what makes retatrutide different from semaglutide and Mounjaro, and it's what makes the open safety signals different too.